What does CNTB do?
Connect Biopharma Holdings, based in San Diego, develops therapies for T cell-driven inflammatory diseases and went public on March 19, 2021. Its lead candidates include rademikibart for atopic dermatitis and asthma, and icanbelimod for ulcerative colitis.
Headquarters
California, USA